Fortress Biotech, INC Form 4 insider transactions

Fortress Biotech's Chief Financial Officer, David Jin, was granted 400,000 restricted stock units as part of his compensation.

Fortress Biotech's Chief Financial Officer, David Jin, acquired 2,967 shares of common stock at $2.176 per share through an employee stock purchase plan.

Fortress Biotech, Inc. increased its beneficial ownership in Avenue Therapeutics, Inc. by 111,209 shares of common stock as an annual dividend.

Fortress Biotech Director Dov Klein was granted 27,322 restricted shares, which were deferred into share units with a vesting schedule through 2029.

Fortress Biotech Director Jimmie Harvey was granted 27,322 restricted shares, deferred into units vesting over three years.

Fortress Biotech Director Kevin Lorenz received a grant of 27,322 restricted common shares under the company's 2013 Stock Incentive Plan.

Fortress Biotech, a 10% owner and director of Mustang Bio, Inc., acquired 278,385 shares of common stock as an annual dividend, increasing its beneficial ownership to 536,577 shares.

Fortress Biotech director Malcolm Hoenlein received a grant of 27,322 restricted shares, vesting over three years, with a portion deferred into share units.

Fortress Biotech Director J. Jay Lobell was granted 27,322 restricted shares, which were deferred into share units vesting over three years.

Fortress Biotech's Chief Financial Officer, David Jin, reported a planned acquisition of 2,711 shares of common stock through the company's Employee Stock Purchase Plan.

Fortress Biotech, a 10% owner and director of Mustang Bio, acquired 59,334 shares of common stock as an equity fee following a warrant exercise by Mustang Bio.

Fortress Biotech, Inc. has reported the complete disposition of its equity stake in Checkpoint Therapeutics, Inc. as a result of Checkpoint's acquisition by Sun Pharmaceutical Industries, Inc. for $4.10 per share in cash plus a contingent value right.

Fortress Biotech, a 10% owner of Mustang Bio, acquired 67,806 shares of common stock as an equity fee and disposed of 198,858 shares on March 31, 2025.

Fortress Biotech, a 10% owner of Avenue Therapeutics, acquired 33,724 shares of common stock on March 31, 2025, as an equity fee related to a financing event.

David Jin, CFO of Fortress Biotech, reports the acquisition of 5,000 shares of common stock through the company's Employee Stock Purchase Plan at a price of $1.2155 per share.

Fortress Biotech, a 10% owner of Checkpoint Therapeutics, acquired 18,500 shares of common stock as an equity fee related to a financing consummated by Checkpoint.

Director J Jay Lobell of Fortress Biotech, Inc. was granted 49,383 shares of restricted stock on January 1, 2025, under the company's 2013 Stock Incentive Plan.

Director Dov Klein acquired 49,383 shares of restricted stock in Fortress Biotech, with vesting occurring over three years.

Director Lu Lucy reports receiving a grant of restricted stock and electing to defer it into share units under Fortress Biotech's compensation plan.

Director Jimmie Harvey received a grant of 49,383 restricted shares of Fortress Biotech stock, which will vest over three years, with the director electing to defer 100% of the shares.

Director Kevin Lorenz receives restricted stock grant and disposes of shares in Fortress Biotech, Inc.

Malcolm Hoenlein, a director at Fortress Biotech, was granted 49,383 shares of restricted stock under the company's 2013 Stock Incentive Plan.

Fortress Biotech, a significant shareholder in Checkpoint Therapeutics, acquired additional shares through equity fee grants related to financing activities and an annual equity fee.

Michael S. Weiss, Executive Vice Chairman of Fortress Biotech, was granted 454,153 restricted shares on January 1, 2025, according to a recent SEC filing.

Fortress Biotech's CEO, Lindsay A. Rosenwald, received 454,153 restricted shares as part of the company's Long-Term Incentive Plan.

David Jin, CFO of Fortress Biotech, was granted 1,000,000 restricted stock units on December 19, 2024, according to a recent SEC filing.

David Jin, CFO of Fortress Biotech, reports acquiring 2,625 shares of common stock at $1.2283 per share under the company's Employee Stock Purchase Plan.

Fortress Biotech, a 10% owner of Checkpoint Therapeutics, acquired 146,341 shares of common stock as an equity fee following the closing of a financing.

Fortress Biotech's CEO, Lindsay Rosenwald, recently acquired shares and warrants of the company's common stock.

Fortress Biotech's CEO, Lindsay A. Rosenwald, sold 5,000 shares of Series A Cumulative Perpetual Preferred Stock at an average price of $7.4835 on July 11, 2024.